BOLT Profile
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company based in Redwood City, California, specializes in developing innovative immuno-oncology therapies designed to harness the body's immune system to target and eliminate cancer cells. Established in 2015, the company focuses on advancing a portfolio of cutting-edge agents aimed at treating various solid tumors by leveraging its proprietary technology platform.
The company's lead product candidate, BDC-1001, is an investigational therapy targeting human epidermal growth factor receptor 2 (HER2), which is currently undergoing Phase I/II clinical trials. This treatment is designed for patients with HER2-expressing solid tumors, including those with low levels of HER2 expression. Another key development is BDC-2034, which targets carcinoembryonic antigen (CEA) and is being evaluated for its efficacy in treating colorectal, non-small cell lung, pancreatic, and breast cancers. Additionally, Bolt Biotherapeutics is advancing BDC-3042, a Dectin-2 agonist antibody program aimed at modulating the tumor microenvironment by repolarizing macrophages through targeting specific cell-surface receptors.
The company is also exploring therapies targeting programmed cell death-ligand 1 (PD-L1) for cancers that are resistant to conventional immune checkpoint inhibitors. This approach is part of Bolt Biotherapeutics' broader strategy to overcome the limitations of current immune-oncology treatments and address unmet medical needs in cancer therapy.
Originally known as Bolt Therapeutics, Inc., the company rebranded as Bolt Biotherapeutics, Inc. in July 2015 to better reflect its focus on the development of biologics for cancer treatment. With a strong pipeline and a commitment to advancing the science of immuno-oncology, Bolt Biotherapeutics is well-positioned to contribute significantly to the field of cancer immunotherapy and improve patient outcomes through its innovative therapeutic approaches.
|
